Actively Recruiting
A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study
Led by Hoffmann-La Roche · Updated on 2026-05-12
100
Participants Needed
58
Research Sites
508 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this extension study is to provide continued treatment with Roche investigational medicinal product (IMP\[s\]) monotherapy or Roche IMP(s) combined with other agent(s) or comparator agent(s) for eligible participants with cancer who are still on study treatment at the time of roll-over from the parent study and who do not have access to the study treatment locally.
CONDITIONS
Official Title
A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Eligible for continuing Roche IMP-based therapy at the time of roll-over from the parent study, as per the parent study protocol OR
- Eligible for continuing the comparator agent(s) in a Genentech- or Roche-sponsored study as per the parent study protocol, with no access to commercially available comparator agent
- First dose of study treatment in this extension study will be received within 7 days of the treatment interruption window allowed by the parent study
- Continue to benefit from the Roche IMP-based therapy or comparator at the time of roll-over from the parent study as assessed by the investigator
- Ability to comply with the extension study protocol, per Investigator's judgement
You will not qualify if you...
- Meet any of the study treatment discontinuation criteria specified in the parent study at the time of enrollment in this extension study
- Study treatment or comparator agent is commercially marketed in the participant's country for the participant-specific disease and is accessible to the participant
- Treatment with any anti-cancer treatment (other than treatment permitted in the parent study) during the time between last treatment in the parent study and the first dose of study treatment in this extension study
- Permanent discontinuation of all study treatment(s) or comparator agent(s) for any reason during the parent study or during the time between last treatment in the parent study and the first dose of study treatment in this extension study (if applicable)
- Ongoing SAE(s) that has not resolved to baseline level or Grade from the parent study or during the time between the last treatment in the parent study and the first dose of study treatment in this extension study
- Concurrent participation in any therapeutic clinical trial (other than the parent study)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 58 locations
1
GHdC Site Les Viviers
Charleroi, Belgium, 6060
Completed
2
AZ Groeninge
Kortrijk, Belgium, 8500
Active, Not Recruiting
3
UZ Leuven Gasthuisberg
Leuven, Belgium, 3000
Completed
4
Princess Margaret Cancer Center
Toronto, Ontario, Canada, M5G 1Z5
Actively Recruiting
5
First Affiliated Hospital of Medical College of Xi'an Jiaotong University
XI 'an City, Shaanxi Province, Shaanxi, China, 710061
Actively Recruiting
6
Beijing Cancer Hospital
Beijing, China, 100142
Actively Recruiting
7
the First Hospital of Jilin University
Changchun, China, 130021
Actively Recruiting
8
West China Hospital of Sichuan University
Chengdu, China, 610041
Actively Recruiting
9
Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
Hangzhou, China, 310016
Actively Recruiting
10
Harbin Medical University Cancer Hospital
Harbin, China, 150081
Actively Recruiting
11
The Second Affiliated Hospital of Anhui Medical University
Hefei, China, 230601
Actively Recruiting
12
Meizhou People's Hospital
Meizhou, China, 514031
Actively Recruiting
13
The 1st Affiliated Hospital of Nanchang Unversity
Nanchang, China, 330052
Actively Recruiting
14
Jiangsu Province Hospital of Chinese Medicine
Nanjing, China, 210029
Actively Recruiting
15
Fudan University Shanghai Cancer Center
Shanghai, China, 200120
Actively Recruiting
16
Shanghai Geriatric Medical Center
Shanghai, China, 201104
Actively Recruiting
17
The First Affiliated Hospital of Xiamen University
Xiamen, China, 361003
Actively Recruiting
18
The First Affiliated Hospital of Xinxiang Medical University
Xinxiang, China
Actively Recruiting
19
Henan Cancer Hospital
Zhengzhou, China, 450008
Actively Recruiting
20
Clinica CIMCA
San José, Costa Rica, 10103
Active, Not Recruiting
21
ICIMED Instituto de Investigación en Ciencias Médicas
San José, Costa Rica, 10108
Active, Not Recruiting
22
Institut Bergonie
Bordeaux, France, 33076
Actively Recruiting
23
Centre Francois Baclesse
Caen, France, 14076
Actively Recruiting
24
Institut de Cancérologie de Bourgogne
Dijon, France, 21000
Actively Recruiting
25
Centre Leon Berard
Lyon, France, 69373
Actively Recruiting
26
Hopital de la Timone
Marseille, France, 13005
Actively Recruiting
27
Centre Régional de Lutte Contre Le Cancer Val D'aurelle Paul Lamarque
Montpellier, France, 34298
Actively Recruiting
28
Institut de cancerologie du Gard
Nîmes, France, 30029
Active, Not Recruiting
29
Hopital Tenon
Paris, France, 75970
Actively Recruiting
30
ICO - Site René Gauducheau
Saint-Herblain, France, 44805
Actively Recruiting
31
Institut Claudius Regaud
Toulouse, France, 31059
Actively Recruiting
32
Gustave Roussy
Villejuif, France, 94800
Actively Recruiting
33
General Hospital "G.Papanikolaou"
Asvestochóri, Greece, 570 10
Actively Recruiting
34
Metropolitan General Hospital
Cholargós, Greece, 155 62
Actively Recruiting
35
Kyushu University Hospital
Fukuoka, Japan, 812-8582
Actively Recruiting
36
Yokohama City University Medical Center
Kanagawa, Japan, 232-0024
Active, Not Recruiting
37
Kanagawa Cancer Center
Kanagawa, Japan, 241-8515
Completed
38
National Cancer Center Hospital East
Kashiwa-shi, Japan, 277-8577
Actively Recruiting
39
Saitama Cancer Center
Saitama, Japan, 362-0806
Actively Recruiting
40
NHO Kinki-Chuo Chest Medical Center
Sakaishi, Japan, 591-8555
Actively Recruiting
41
Centro Medico Culiacan SA de CV
Culiacán, Sinaloa, Mexico
Active, Not Recruiting
42
Medical Care & Research
Mérida, Yucatán, Mexico, 97070
Completed
43
Consultorio de Especialidad en Urologia Privado
Durango, Mexico, 34000
Active, Not Recruiting
44
Narodowy Instytut Onkologii im. M.Sklodowskiej-Curie
Warsaw, Poland, 02-781
Actively Recruiting
45
Moscow City Oncology Hospital #62
Moscovskaya Oblast, Moscow Oblast, Russia, 143423
Actively Recruiting
46
Russian Scientific Center of Roentgenoradiology
Moscow, Moscow Oblast, Russia, 117997
Active, Not Recruiting
47
P.A. Herzen Oncological Inst.
Moscow, Moscow Oblast, Russia, 125248
Actively Recruiting
48
Seoul National University Bundang Hospital
Seongnam-si, South Korea, 463-707
Completed
49
Asan Medical Center
Seoul, South Korea, 05505
Active, Not Recruiting
50
Taichung Veterans General Hospital
Taichung, Taiwan, 407
Actively Recruiting
51
National Cheng Kung University Hospital
Tainan, Taiwan, 70457
Actively Recruiting
52
National Taiwan University Hospital
Taipei, Taiwan, 110
Actively Recruiting
53
Chang Gung Memorial Hospital - Linkou
Taoyuan, Taiwan, 333
Active, Not Recruiting
54
Chulalongkorn Hospital
Bangkok, Thailand, 10330
Active, Not Recruiting
55
Siriraj Hospital
Bangkok, Thailand, 10700
Actively Recruiting
56
Maharaj Nakorn Chiangmai Hospital
Chiang Mai, Thailand, 50200
Active, Not Recruiting
57
Leicester Royal Infirmary
Leicester, United Kingdom, LE1 5WW
Actively Recruiting
58
Royal Marsden Hospital - Surrey
Surrey, United Kingdom, SM2 5PT
Completed
Research Team
R
Reference Study ID Number: BX44273 https://forpatients.roche.com/
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here